2026-01-22 - Analysis Report
**Financial Report for Abbott Laboratories (ABT)**

**Company Overview:** Abbott Laboratories is a multinational pharmaceutical, medical device, and nutritional products company.

**Return Rate Comparison**

- Cumulative return of review stock (ABT): 31.42%
- Cumulative return of comparison stock (S&P 500, VOO): 91.55%
- Divergence: -60.80 (max: 37.10, min: -60.80)
- Rate vs (rate of S&P 500): -50.13 (91.55 - 31.42)

The divergence indicates a 60.80% difference between the return rate of ABT and VOO, with ABT underperforming VOO.

**Alpha, Beta Analysis**

| Year | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------|------|------|-------|------|-------|
| 2016-2018 | 32.0% | 14.5% | 28.0% | 1.1 | 125.9B |
| 2017-2019 | 41.0% | 14.5% | 24.0% | 1.0 | 151.2B |
| 2018-2020 | -1.0% | 16.8% | -22.0% | 0.9 | 190.6B |
| 2019-2021 | 42.0% | 16.8% | -2.0% | 0.8 | 244.9B |
| 2020-2022 | -20.0% | 28.8% | -18.0% | 0.8 | 191.1B |
| 2021-2023 | -22.0% | 28.8% | -23.0% | 0.7 | 191.6B |
| 2022-2024 | -31.0% | 24.3% | -50.0% | 0.7 | 196.9B |
| 2023-2025 | 10.0% | 16.0% | -52.0% | 0.3 | 218.1B |

The Beta value indicates that ABT historically has a high sensitivity to market fluctuations.

**Recent Stock Price Fluctuations**

* Close: $120.73
* 5-day SMA: $122.43
* 20-day SMA: $124.68
* 60-day SMA: $125.71

The stock price is currently trending above the 5-day SMA, but below the 20-day and 60-day SMAs.

**RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence, Expected_Return**

* Market Risk Indicator (MRI): 0.80
* RSI: 31.47
* PPO: -0.41
* Risk Level: Medium (MRI 0.80)
* Recent (20 days) relative divergence change: -2.00
* 7-day Rank change: 50
* 7-day Dynamic Expected Return change: 0.80
* Expected Return: -1605.30%

The PPO and RSI values indicate that the stock is currently oversold.

**Recent News & Significant Events**

* [2026-01-21] Abbott Laboratories $ABT Stock Position Lifted by Vest Financial LLC
* [2026-01-21] Is Abbott Laboratories (ABT) Pricing Reflect Its Medical Device And Diagnostics Momentum?
* [2026-01-21] Abbott Laboratories Q4 2025 Earnings Preview (ABT:NYSE)
* [2026-01-21] Wall Street Analysts Think Abbott (ABT) Is a Good Investment: Is It?

These news articles suggest that Abbott Laboratories is a promising investment opportunity.

**Analyst Opinions**

* Analyst Consensus: Buy
* Mean (1=StrongBuy~5=Sell): 1.76 (~Buy)
* Opinions: 25
* Target Price (avg/high/low): 144.75 / 169.00 / 122.00

The analyst consensus is to buy the stock, with a target price of $144.75.

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|---|---:|---:|
| 2025-10-29 | 0.94 | 11.37 B$ |
| 2025-07-30 | 1.02 | 11.14 B$ |
| 2025-04-30 | 0.76 | 10.36 B$ |
| 2024-10-31 | 0.94 | 10.63 B$ |

The EPS and revenue growth rates have decreased in the last two quarters.

**Financial Information: Revenue and Profitability**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $11.37B | 55.36% |
| 2025-06-30 | $11.14B | 56.44% |
| 2025-03-31 | $10.36B | 56.86% |
| 2024-12-31 | $10.97B | 54.97% |
| 2024-09-30 | $10.63B | 55.83% |

The profit margins have consistently remained above 55%, indicating a stable profitability.

**Financial Information: Capital and Profitability**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $50.95B | 3.23% |
| 2025-06-30 | $50.56B | 3.52% |
| 2025-03-31 | $48.81B | 2.71% |
| 2024-12-31 | $47.66B | 19.36% |
| 2024-09-30 | $39.80B | 4.14% |

The ROE has decreased in the last two quarters, but is still indicating a relatively stable financial position.

**Comprehensive Analysis (Summary of previous items)**

Based on the previous items, Abbott Laboratories has a stable profitability, but a decreasing EPS and revenue growth rate. The stock price has trended below the 20-day and 60-day SMAs, and the PPO and RSI values indicate that the stock is currently oversold. However, the analyst consensus is to buy the stock, with a target price of $144.75.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.